Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roivant Sciences Ltd (NQ: ROIV ) 11.57 -0.20 (-1.70%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Roivant Sciences Ltd < Previous 1 2 Next > Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% September 18, 2024 From Roivant Sciences Via GlobeNewswire Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress September 10, 2024 From Roivant Sciences Via GlobeNewswire Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator September 10, 2024 From Roivant Sciences Via GlobeNewswire Roivant Provides Update on Graves’ Disease Development Program September 09, 2024 From Roivant Sciences Via GlobeNewswire Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update August 08, 2024 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 July 25, 2024 From Roivant Sciences Via GlobeNewswire Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update May 30, 2024 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 May 16, 2024 From Roivant Sciences Via GlobeNewswire Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million April 02, 2024 From Roivant Sciences Via GlobeNewswire Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update February 13, 2024 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 January 30, 2024 From Roivant Sciences Via GlobeNewswire Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease December 20, 2023 From Roivant Sciences Via GlobeNewswire Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease December 14, 2023 From Roivant Sciences Via GlobeNewswire Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential November 28, 2023 From Roivant Sciences Via GlobeNewswire Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus November 27, 2023 From Roivant Sciences Via GlobeNewswire Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update November 13, 2023 From Roivant Sciences Via GlobeNewswire Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors November 10, 2023 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 October 30, 2023 From Roivant Sciences Via GlobeNewswire Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant October 23, 2023 From Roivant Sciences Via GlobeNewswire Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer October 13, 2023 From Covant Therapeutics Via GlobeNewswire Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results September 26, 2023 From Roivant Sciences Via GlobeNewswire Roivant Announces Completion of Redemption of its Outstanding Warrants September 11, 2023 From Roivant Sciences Via GlobeNewswire Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants August 17, 2023 From Roivant Sciences Via GlobeNewswire Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update August 14, 2023 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023 August 03, 2023 From Roivant Sciences Via GlobeNewswire Roivant Announces Redemption of Outstanding Warrants August 02, 2023 From Roivant Sciences Via GlobeNewswire Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease July 27, 2023 From Roivant Sciences Via GlobeNewswire Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program July 11, 2023 Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others From Roivant Sciences Via GlobeNewswire UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update June 28, 2023 From Roivant Sciences Via GlobeNewswire Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update June 28, 2023 From Roivant Sciences Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.